"10.1371_journal.pone.0090031","plos one","2014-02-27T00:00:00Z","Arturo Bravo-Nuevo; Alice Marcy; Minzhou Huang; Frank Kappler; Jennifer Mulgrew; Lisa Laury-Kleintop; Melvin Reichman; Annette Tobia; George C Prendergast","Lankenau Institute for Medical Research (LIMR), Wynnewood, Pennsylvania, United States of America; Dynamis Pharmaceuticals Co. Inc., Jenkintown, Pennsylvania, United States of America; LIMR Chemical Genomics Center Inc., Wynnewood, Pennsylvania, United States of America","Conceived and designed the experiments: ABN AM LLK GP AT. Performed the experiments: ABN AM FK JM MH. Analyzed the data: ABN AM FK LLK. Contributed reagents/materials/analysis tools: ABN GP AT LLK JM. Wrote the paper: ABN MR AM GP.","This work was funded by a grant from Dynamis Therapeutics Inc. Alice Marcy, Frank Kappler and Annette Tobia are employed by Dynamis Pharmaceuticals Co. Inc. and own shares of Dynamis Therapeutics Inc. Dynamics Pharmaceuticals markets products based on meglumine. George C. Prendergast and Melvin Reichman are employed respectively by the Lankenau Institute for Medical Research (LIMR) and the LIMR Chemical Genomics Center Inc. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","02","Arturo Bravo-Nuevo","ABN",9,TRUE,5,5,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
